Hereditary Breast Cancer Prevention
The clinical research activity centers on breast cancer prevention in women with a BRCA1 germline mutation, with a focus on reducing the risk of invasive breast cancer and ductal carcinoma in situ.
- BRCA1-associated cancer risk
- Primary prevention of breast cancer
- Non-malignant and pre-invasive breast lesions
This area reflects a strong interest in genetic susceptibility and cancer prevention strategies for women at elevated inherited risk.
Oncology Risk Reduction
The sponsor is involved in oncology research aimed at lowering future cancer occurrence rather than treating established disease, with emphasis on risk reduction in a high-risk population.
- Cancer incidence reduction
- High-risk women’s health
- Preventive oncology
The research setting includes collaboration across multiple sites, supporting clinical investigation in preventive cancer care.
Targeted Bone-Related Therapeutic Interest
Clinical interest extends to the use of denosumab, a therapy commonly associated with bone metabolism, within a cancer prevention context for women carrying BRCA1 mutations.
- Denosumab-based prevention
- Bone signaling pathways
- Mechanism-driven cancer prevention
This links the sponsor’s work to biologically targeted approaches relevant to breast carcinogenesis.
Multicenter Clinical Collaboration
The sponsor participates in a multicenter clinical research network spanning several countries and collaborating sites, with activity coordinated through a hospital-based research unit in L’Hospitalet de Llobregat, Spain.
- International site collaboration
- Hospital-based research infrastructure
- Cross-border oncology studies
The research landscape is concentrated in a single active study area, focused on hereditary breast cancer prevention.
